Leading cannabis Lawyer Robert Jappie of law firm Ince reflects on the shifting status of CBD in Europe
THE European Commission has paused consideration of the majority of CBD Novel Food submissions. Its announcement to potentially reclassify CBD as a narcotic is a real concern for the whole European CBD industry.
Businesses that submitted an application to the EC have each received a letter advising them of the decision to pause the validation process on the basis that consideration is being given to reclassifying CBD as a narcotic.
If this reclassification were to take place CBD could be treated in the same way as THC, under the UN Convention on Narcotic Drugs. This would mean that CBD could not be used in foods. It would also impact upon the use of CBD in cosmetics and vape products.
UK FSA Position
Whilst the UK is in the Brexit transition period, the FSA cannot formally (or legally) accept Novel Food dossiers. However the FSA has confirmed it will informally accept dossiers until the end of 2020.
If a company does informally submit their dossier with the FSA before December 31, 2020, then the FSA will review the dossier and provide feedback on where improvements can/should be made.
This will then give companies time to update their dossiers and formally submit a good quality dossier to the FSA in January. A good quality dossier – especially under the guidance of FSA – means that it is possible to speed up the time from submission to approval.
The FSA will not extend the March 31, 2021, deadline for dossiers to be validated. Paul Tossell who heads up the Novel Food department at the FSA has been categorical about this.
As of approximately two months ago, the FSA had already received eight dossiers submissions. Mr Tossell was adamant that the FSA has the capacity to validate dossiers in time for the March 31, 2021, deadline. To help meet this deadline, however, companies should informally submit their dossiers to the FSA by December 31, 2020, and, ideally as soon as possible.
The FSA has advised that there is no likelihood that the UK Home Office will follow the EC route. They have been very clear that CBD (without any psychotropic properties) is not a narcotic and therefore, not a controlled drug.
The MHRA (Medicines and Healthcare products Regulatory Agency) has confirmed that CBD without any medical claims, is not a medicine. This means all that is left is classification as a ‘food’, and because there is no history of use prior to May 1997, CBD is a novel food.
EU EFSA Position
Businesses have invested a great deal of time and money in establishing operations across Europe in the CBD wellness sector.
It would be entirely inappropriate for the EC to now attempt a reclassification, particularly as CBD was deemed a novel food as long ago as January 2019.
However, as the EC has not yet fixed its position, there is no formal legal challenge available at this time. It seems likely that any efforts to reclassify CBD as a narcotic will be strongly resisted by business in Europe, and via litigation if necessary.
To be novel food approved throughout Europe then a dossier must be submitted to the EC. It is a commercial decision as to whether the company makes a submission to the EC now knowing that it will be ‘paused’ whilst the EC determines if CBD is a narcotic or not.
We can still submit to the EC now. The advantage of submitting to the EC now is that your dossier will already be in the queue for validation should they determine CBD is not a narcotic.
CND Session In Vienna
Something else to consider is the UN Commission on Narcotic Drugs (CND) session in Vienna later this year. The World Health Organisation (WHO) has recommended amending Schedule I of the 1961 UN Single Convention on Narcotic Drugs in order to clarify that cannabidiol (CBD) is not a narcotic drug. The WHO proposals read:
Proposal 5.4: Delete extracts and tinctures of cannabis from Schedule I of the 1961 Convention
Proposal 5.5: Add a footnote on cannabidiol preparations to Schedule I of the 1961 Convention to read: “Preparations containing predominantly cannabidiol and not more than 0.2 per cent of delta-9- tetrahydrocannabidiol are not under international control”
This will be considered by the CND in December 2020. There is some debate as to whether these proposals will benefit the CBD industry if adopted. Either way, it should be an interesting end to an eventful year.
CBD A Narcotic? Expect A Legal Challenge If EC Proceeds With This Classification – UK Lawyer Robert Jappie
Leading cannabis Lawyer Robert Jappie of law firm Ince reflects on the shifting status of CBD in Europe
THE European Commission has paused consideration of the majority of CBD Novel Food submissions. Its announcement to potentially reclassify CBD as a narcotic is a real concern for the whole European CBD industry.
Businesses that submitted an application to the EC have each received a letter advising them of the decision to pause the validation process on the basis that consideration is being given to reclassifying CBD as a narcotic.
If this reclassification were to take place CBD could be treated in the same way as THC, under the UN Convention on Narcotic Drugs. This would mean that CBD could not be used in foods. It would also impact upon the use of CBD in cosmetics and vape products.
UK FSA Position
Whilst the UK is in the Brexit transition period, the FSA cannot formally (or legally) accept Novel Food dossiers. However the FSA has confirmed it will informally accept dossiers until the end of 2020.
If a company does informally submit their dossier with the FSA before December 31, 2020, then the FSA will review the dossier and provide feedback on where improvements can/should be made.
This will then give companies time to update their dossiers and formally submit a good quality dossier to the FSA in January. A good quality dossier – especially under the guidance of FSA – means that it is possible to speed up the time from submission to approval.
The FSA will not extend the March 31, 2021, deadline for dossiers to be validated. Paul Tossell who heads up the Novel Food department at the FSA has been categorical about this.
As of approximately two months ago, the FSA had already received eight dossiers submissions. Mr Tossell was adamant that the FSA has the capacity to validate dossiers in time for the March 31, 2021, deadline. To help meet this deadline, however, companies should informally submit their dossiers to the FSA by December 31, 2020, and, ideally as soon as possible.
The FSA has advised that there is no likelihood that the UK Home Office will follow the EC route. They have been very clear that CBD (without any psychotropic properties) is not a narcotic and therefore, not a controlled drug.
The MHRA (Medicines and Healthcare products Regulatory Agency) has confirmed that CBD without any medical claims, is not a medicine. This means all that is left is classification as a ‘food’, and because there is no history of use prior to May 1997, CBD is a novel food.
EU EFSA Position
Businesses have invested a great deal of time and money in establishing operations across Europe in the CBD wellness sector.
It would be entirely inappropriate for the EC to now attempt a reclassification, particularly as CBD was deemed a novel food as long ago as January 2019.
However, as the EC has not yet fixed its position, there is no formal legal challenge available at this time. It seems likely that any efforts to reclassify CBD as a narcotic will be strongly resisted by business in Europe, and via litigation if necessary.
To be novel food approved throughout Europe then a dossier must be submitted to the EC. It is a commercial decision as to whether the company makes a submission to the EC now knowing that it will be ‘paused’ whilst the EC determines if CBD is a narcotic or not.
We can still submit to the EC now. The advantage of submitting to the EC now is that your dossier will already be in the queue for validation should they determine CBD is not a narcotic.
CND Session In Vienna
Something else to consider is the UN Commission on Narcotic Drugs (CND) session in Vienna later this year. The World Health Organisation (WHO) has recommended amending Schedule I of the 1961 UN Single Convention on Narcotic Drugs in order to clarify that cannabidiol (CBD) is not a narcotic drug. The WHO proposals read:
Proposal 5.4: Delete extracts and tinctures of cannabis from Schedule I of the 1961 Convention
Proposal 5.5: Add a footnote on cannabidiol preparations to Schedule I of the 1961 Convention to read: “Preparations containing predominantly cannabidiol and not more than 0.2 per cent of delta-9- tetrahydrocannabidiol are not under international control”
This will be considered by the CND in December 2020. There is some debate as to whether these proposals will benefit the CBD industry if adopted. Either way, it should be an interesting end to an eventful year.
Understanding cannabis sales growth in June and July in Canada
Next PostHow retail tech leads to world class consumer insights
Peter
Related Posts
Related Posts
Cannabis Rescheduling: DEA’s Decision Marks a New Era for the Industry
The US Drug Enforcement Administration (DEA) is set to approve the rescheduling of cannabis in a move set to have...
Germany’s ‘Pillar 2’ Is Already Being Worked On and Could Be Here Far Sooner Than Expected
Germany’s highly anticipated ‘Pillar 2’, which would seek to implement a Switzerland-style adult-use cannabis pilot project model, is now being...
Cannabis Rescheduling: Rumours Swirl on Imminent DEA Announcement as Legal Experts Expected to Weigh In
Germany’s Predicted Medical Cannabis Boom Is in Full Swing Following Passage of CanG
SAFER Banking Act Faces Last-Minute Opposition, Derails FAA Bill Plans
Hawaii Lawmakers Shoot Down Second Cannabis Reform Bill This Month
CONNECT
Related Posts
Related Posts
Cannabis Rescheduling: DEA’s Decision Marks a New Era for the Industry
The US Drug Enforcement Administration (DEA) is set to approve the rescheduling of cannabis in a move set to have...
Germany’s ‘Pillar 2’ Is Already Being Worked On and Could Be Here Far Sooner Than Expected
Germany’s highly anticipated ‘Pillar 2’, which would seek to implement a Switzerland-style adult-use cannabis pilot project model, is now being...
Cannabis Rescheduling: Rumours Swirl on Imminent DEA Announcement as Legal Experts Expected to Weigh In
Click here for the latest on the DEA's decision on cannabis rescheduling. Rumours are once again swirling that a decision...
Germany’s Predicted Medical Cannabis Boom Is in Full Swing Following Passage of CanG
It has been almost exactly a month since Germany’s CanG came into effect, making adult-use consumption and possession legal, within...
SAFER Banking Act Faces Last-Minute Opposition, Derails FAA Bill Plans
Hopes that the highly anticipated SAFER Banking Act could be attached to a ‘must pass’ bill were scuppered last week...
Recent Posts
Related Posts
‘Landmark’ Ruling Gives Hope For UK CBD Flower Businesses
A ‘landmark’ Court of Appeal ruling in the UK has set a new legal precedent for businesses in the UK...
European Hemp Leaders Launch Bid To Designate ‘Natural’ CBD A Traditional Food
EUROPEAN hemp leaders are to open a new front in the on-going continental cannabidiol (CBD) battle by looking to have...
Temporary Framework In Lieu Of Novel Foods Regulation Allows CBD To Be Registered As Food Supplement In France
FRENCH authorities have implemented a new ‘temporary framework’ for CBD allowing it to be registered and sold as a food...
Ireland’s ‘Dangerously Confused’ Justice System Is Harming Europe’s Hemp And CBD Industry
Chris Allen, Executive Director of Hemp Federation Ireland, elaborates on the Irish authorities’ legal turmoil over hemp and CBD. HEMP Federation...
Ireland’s Prohibitionist Approach To Hemp And CBD Exposes It To Punitive Sanctions From The EU
A HIGH Court decision to ignore the ground-breaking KanaVape case could expose the Irish Government to financial penalties and the...
Subscribe to our mailing list to receives daily updates!
We won’t spam you
Categories
Browse by Tags